Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.
The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.
Hahmann
C
C
Discovery Biology, Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, Jupiter, FL 33458, USA.
Schroeter
T
T
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000201:enzymology; D004285:Dogs; D005901:Glaucoma / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000737:chemistry; D007674:Kidney Diseases / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry
D007527:Isoenzymes; D047428:Protein Kinase Inhibitors; D054460:rho-Associated Kinases